Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.
Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.
Johnson
Alan P
AP
Health Protection Agency Centre for Infections, Department of Healthcare-Associated Infection and Antimicrobial Resistance, 61 Colindale Avenue, London NW9 5EQ, UK. alan.johnson@hpa.org.uk
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016360:Clostridioides difficile / Q000187:drug effects / Q000254:growth & development; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology; D004353:Drug Evaluation, Preclinical; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy / Q000382:microbiology; D006027:Glycosides / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans
D000900:Anti-Bacterial Agents; D006027:Glycosides; C487655:OPT 80